A Phase 2 interventional study of Pemetrexed and Cisplatin in Non-small Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 7 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-09-09.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 21 open to participants now, 32 under way, 11 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.
Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 105th largest by enrollment of the 223 interventional ones that give a count, is one of 12 that started in 2007, is one of 128 in phase 2, and was the 48th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →21 of the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Belgium, Brazil and 17 more countries
Ages 18+
Guangzhou Medical University · Sites in China
Ages 18–75
Second Affiliated Hospital of Nanchang University · Sites in China
Ages 18–85
Shanghai Chest Hospital · Sites in China
Ages 18+
Taipei Veterans General Hospital, Taiwan · Sites in Taiwan
Ages 20+
By country, each count listing its studies:
Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
227 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 148 · Phase 3 47 · Phase 4 8
First in 2001; this study’s year is marked. 12 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 70 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 64 across the 223 interventional studies. Of the 161 that completed or were terminated, 89 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 227 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company: 6 open now, 20 under way, 6 of them phase 3. Of 121 finished, 81 (67%) have results posted.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 86th largest by enrollment of the 139 interventional ones that give a count, is one of 9 that started in 2007, is one of 73 in phase 2, and was the 46th registered.
Eli Lilly and Company’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
7 of the studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04585490Phase 3Stanford UniversityAdaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC | 2026-12 |
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT03178552Phase 3Hoffmann-La RocheA Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | 2027-06-30 |
| NCT05805631Taipei Veterans General Hospital, TaiwanIntrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC | 2026-12-31 |
| NCT06440954Hunan Province Tumor HospitalEfficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Eli Lilly and Company’s 147 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the efficacy and safety of chemotherapy followed sequentially by gefitinib versus chemotherapy alone in the first line treatment of non-small cell lung cancer (NSCLC). This study will be conducted in Asian patients who are classified as 'never smoker' since it is suggested that these patients are more likely to respond favorably to treatment with gefitinib.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pemetrexed 500 milligrams per meters squared (mg/m2) plus cisplatin 75 mg/m2 administered by intravenous (IV) infusion once every 3 weeks for 4 cycles without progression followed by gefitinib 250 mg administered orally, once daily, until disease progression or unacceptable toxicity.
Drug: Pemetrexed · Drug: Cisplatin · Drug: Gefitinib
Pemetrexed 500 milligrams per meters squared (mg/m2) plus cisplatin 75 mg/m2 administered by intravenous (IV) infusion once every 3 weeks for 4 cycles without progression followed by pemetrexed 500 mg/m2 administered by IV infusion (with optional cisplatin 75 mg/m2 for up to 2 additional cycles) until disease progression or unacceptable toxicity.
Drug: Pemetrexed · Drug: Cisplatin
500 milligrams per meter squared (mg/m2), administered by intravenous (IV) infusion every 21 days for 4 cycles (1-4) or 500 mg/m2, IV, every 21 days until disease progression or unacceptable toxicity.
Also known as: LY231514, Alimta
75 mg/m2, IV, every 21 days for 4 cycles (1-4) or 75 mg/m2, IV, every 21 days for 4 cycles with optional continuation for 2 additional cycles until disease progression or unacceptable toxicity
250 mg, administered orally once daily beginning at Cycle 5 until disease progression or unacceptable toxicity
Progression-Free Survival (PFS)
Defined as the time from randomization to the first observation of disease progression, or death due to any cause.
Time frame: Baseline to first observation of disease progression or death, 12 weeks up to 31 months
Number of Participants With Tumor Response
Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes not meeting above criteria. Responder is a participant exhibiting a best overall study response of CR or PR.
Time frame: Baseline to measured response or death, 12 weeks up to 31 months
Duration of Response for Responders
The duration of a complete response (CR; the disappearance of all target lesions) or partial response (PR; at least a 30% decrease in the sum of the longest diameter of target lesions) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause. A responder is a patient exhibiting a best overall study response of CR or PR.
Time frame: Time of response to progressive disease or death, 12 weeks up to 31 months
Overall Survival
Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact. Median overall survival could not be estimated as most participants were living at the end of the study. 25 participants from each treatment group were censored. In place of this outcome measure, the percentage of participants who died during the study are provided in the Post-Hoc Analysis Outcome Measure: Percentage of Participants Who Died During the Study.
Time frame: Baseline to date of death from any cause, 12 weeks up to 31 months
| Milestone | Pemetrexed/Cisplatin/Gefitinib | Pemetrexed/Cisplatin |
|---|---|---|
| Started | 39 | 31 |
| Completed | 19 | 19 |
| Not completed | 20 | 12 |
| Withdrew: Death | 15 | 6 |
| Withdrew: Lost to follow-up | 1 | 2 |
| Withdrew: Withdrawal by subject | 3 | 2 |
| Withdrew: Physician decision | 1 | 2 |
Defined as the time from randomization to the first observation of disease progression, or death due to any cause.
| Months | Pemetrexed/Cisplatin/Gefitinib | Pemetrexed/Cisplatin |
|---|---|---|
| Progression-Free Survival (PFS) | 9.95 (5.85 to 16.49) | 6.83 (5.78 to 7.98) |
Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes not meeting above criteria. Responder is a participant exhibiting a best overall study response of CR or PR.
| Participants | Pemetrexed/Cisplatin/Gefitinib | Pemetrexed/Cisplatin |
|---|---|---|
| Number of Participants With Tumor Response | 18 (30.1 to 62.8) | 11 (19.2 to 54.6) |
The duration of a complete response (CR; the disappearance of all target lesions) or partial response (PR; at least a 30% decrease in the sum of the longest diameter of target lesions) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause. A responder is a patient exhibiting a best overall study response of CR or PR.
| Months | Pemetrexed/Cisplatin/Gefitinib | Pemetrexed/Cisplatin |
|---|---|---|
| Duration of Response for Responders | 12.29 (8.51 to 15.31) | 4.14 (2.76 to 7.62) |
This outcome measure takes the place of the outcome measure for Overall Survival, which could not be reported since the median value could not be calculated.
| Percentage of Participants | Pemetrexed/Cisplatin/Gefitinib | Pemetrexed/Cisplatin |
|---|---|---|
| Percentage of Participants Who Died During the Study | 35.9 | 19.4 |
Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact. Median overall survival could not be estimated as most participants were living at the end of the study. 25 participants from each treatment group were censored. In place of this outcome measure, the percentage of participants who died during the study are provided in the Post-Hoc Analysis Outcome Measure: Percentage of Participants Who Died During the Study.
No measurements were reported for this outcome.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pemetrexed/Cisplatin/Gefitinib | — | 6/39 (15.4%) | 38/39 (97.4%) |
| Pemetrexed/Cisplatin | — | 3/31 (9.7%) | 31/31 (100%) |
| Event | Pemetrexed/Cisplatin/Gefitinib | Pemetrexed/Cisplatin |
|---|---|---|
| NauseaGastrointestinal disorders | 1/39 | 1/31 |
| VomitingGastrointestinal disorders | 1/39 | 1/31 |
| InfectionInfections and infestations | 0/39 | 1/31 |
| HeadacheNervous system disorders | 1/39 | 1/31 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/39 | 1/31 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 0/39 | 1/31 |
| DeathGeneral disorders | 1/39 | 0/31 |
| PyrexiaGeneral disorders | 1/39 | 0/31 |
| Acute tonsillitisInfections and infestations | 1/39 | 0/31 |
| AnorexiaMetabolism and nutrition disorders | 1/39 | 0/31 |
| Event | Pemetrexed/Cisplatin/Gefitinib | Pemetrexed/Cisplatin |
|---|---|---|
| NauseaGastrointestinal disorders | 27/39 | 20/31 |
| VomitingGastrointestinal disorders | 19/39 | 15/31 |
| AnorexiaMetabolism and nutrition disorders | 19/39 | 15/31 |
| Neutrophil count decreasedInvestigations | 8/39 | 13/31 |
| PruritusSkin and subcutaneous tissue disorders | 14/39 | 5/31 |
| Haemoglobin decreasedInvestigations | 8/39 | 11/31 |
| RashSkin and subcutaneous tissue disorders | 13/39 | 6/31 |
| White blood cell count decreasedInvestigations | 6/39 | 8/31 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 6/39 | 8/31 |
| DiarrhoeaGastrointestinal disorders | 10/39 | 3/31 |
| Age Continuous(years) | Pemetrexed/Cisplatin/Gefitinib | Pemetrexed/Cisplatin | Total |
|---|---|---|---|
| Mean | 55.6 ± 8.45 | 55.7 ± 12.43 | 55.7 ± 10.32 |
| Sex: Female, Male(Participants) | Pemetrexed/Cisplatin/Gefitinib | Pemetrexed/Cisplatin | Total |
|---|---|---|---|
| Female | 30 | 25 | 55 |
| Male | 9 | 6 | 15 |
| Race/Ethnicity, Customized(Participants) | Pemetrexed/Cisplatin/Gefitinib | Pemetrexed/Cisplatin | Total |
|---|---|---|---|
| East Asian | 39 | 31 | 70 |
| Region of Enrollment(participants) | Pemetrexed/Cisplatin/Gefitinib | Pemetrexed/Cisplatin | Total |
|---|---|---|---|
| Taiwan | 10 | 11 | 21 |
| China | 16 | 14 | 30 |
| Korea, Republic of | 13 | 6 | 19 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(Units on a scale) | Pemetrexed/Cisplatin/Gefitinib | Pemetrexed/Cisplatin | Total |
|---|---|---|---|
| 0 | 15 | 9 | 24 |
| 1 | 24 | 22 | 46 |
| History of Smoking(Participants) | Pemetrexed/Cisplatin/Gefitinib | Pemetrexed/Cisplatin | Total |
|---|---|---|---|
| Yes | 0 | 2 | 2 |
| No | 39 | 29 | 68 |
| Basis of Diagnosis(Participants) | Pemetrexed/Cisplatin/Gefitinib | Pemetrexed/Cisplatin | Total |
|---|---|---|---|
| Histopathological | 30 | 22 | 52 |
| Cytological | 9 | 9 | 18 |
| Pathological Diagnosis(Participants) | Pemetrexed/Cisplatin/Gefitinib | Pemetrexed/Cisplatin | Total |
|---|---|---|---|
| Mixed Cell Carcinoma, Lung | 1 | 1 | 2 |
| Adenocarcinoma | 30 | 24 | 54 |
| Carcinoma, Squamous Cell | 7 | 4 | 11 |
| Non-Small Cell Lung Carcinoma | 1 | 2 | 3 |
1 further baseline measures are reported on the registry.
The record gives a start of Feb 2007, a primary completion of Aug 2009 and a completion of May 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2010, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pemetrexed · Cisplatin
Carcinoma, Non-Small-Cell Lung →